Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase Inhibitor in Patients With Previously Treated Unresectable Solid Tumours

NCT05826600 is registered in ClinicalTrials.gov with iOmx Therapeutics AG as lead sponsor.

NCT NCT05826600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05826600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/Ib Dose Escalation and Cohort Expansion Study of OMX-0407 a Salt-inducible Kinase Inhibitor in Patients With Previously Treated Unresectable Solid Tumours
Lead sponsor
iOmx Therapeutics AG
Phase
Phase 1/2
Overall status
Terminated
Start date
March 30, 2023
Completion date
April 2, 2026
Enrollment
68 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor